Eli Lilly and Company’s Stock Price Soars to $766.68, Marking a Significant 4.31% Increase

Eli Lilly and Company (LLY)

766.68 USD +31.71 (+4.31%) Volume: 3.4M

Eli Lilly and Company’s stock price soars to 766.68 USD, marking a positive trading session with a 4.31% surge and a notable YTD increase of 31.52%, backed by a robust trading volume of 3.4M, showcasing the pharmaceutical giant’s strong market performance.

Latest developments on Eli Lilly and Company

As Eli Lilly & Co. prepares for the Donanemab Adcomm, the FDA is considering changes to its format. This comes alongside the company declaring a $1.30 quarterly dividend, indicating a 0.7% yield. Eli Lilly is also making waves with another potential blockbuster in the works, attracting significant bets from major investors. The pharmaceutical giant has further declared its second-quarter 2024 dividend and raised its outlook, prompting speculation on whether now is the right time to invest in its stock.

A look at Eli Lilly and Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Eli Lilly & Company seems to have a positive long-term outlook. The company scores high in momentum, indicating strong market performance and investor interest. Additionally, Eli Lilly scores well in growth, suggesting potential for expansion and profitability in the future. Although the company’s value, dividend, and resilience scores are not as high, the overall outlook appears promising for Eli Lilly.

Eli Lilly & Company is a pharmaceutical company that focuses on discovering, developing, and selling a wide range of products for both humans and animals. Their products are distributed globally, covering various medical fields such as neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health. With a strong momentum score and promising growth potential, Eli Lilly is positioned well for continued success in the pharmaceutical industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma